ESC 2018 In an analysis of four large global studies, higher healthy diet score was related to a lower risk of mortality, MI and stroke. Dr. Mente discusses how the healthy diet score is calculated and talks about the results of these four studies.

ESC 2018 One large randomized trial showed that use of aspirin for primary prevention reduced CV events in a diabetes population but at the cost of bleeding, and another resulted in no CV benefit in individuals with moderate CV risk.

A nationwide cohort study showed no excess risk of death, stroke and MI in T2DM patients with five risk-factor variables within guideline-recommended target ranges, compared to general Swedish population.

An analysis of a large population-based study showed that reduced sodium intake is associated with an increased CV risk and an increased sodium intake is associated with an increase in stroke.

In patients with minor ischemic stroke or high-risk TIA, treatment with clopidogrel and aspirin was associated with lower risk of major ischemic events, but higher risk of major and minor hemorrhages.

In a prospective study, LDL-TG levels were associated with an increased risk of CVD, including CHD and ischemic stroke. Lower LDL-TG levels were observed in individuals with the APOE ε2/2 haplotype.

In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

In the LEADER trial, patients with severe hypoglycemia episodes had a higher risk of CV events and mortality compared with patients without severe hypoglycemia, independent of treatment group.

Several reproductive factors, including early menarche, a history of miscarriage or hysterectomy, earlier age at first birth, or an early menopause, were associated with an increased CV risk in later life.

In a pooled analysis of databases of 6 different countries, the initiation of SGLT2i was associated with lower risks of CV outcomes, as compared with other glucose-lowering drugs.

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.